Alternative splicing and retinal degeneration


  • M M Liu,

    1. Wilmer Eye Institute
    Search for more papers by this author
  • D J Zack

    Corresponding author
    1. Department of Molecular Biology and Genetics
    2. Department of Neuroscience
    3. McKusick-Nathans Institute of Genetic Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
    4. Institut de la Vision, Université Pierre et Marie Curie, Paris, France
    • Wilmer Eye Institute
    Search for more papers by this author

  • Nothing to declare.

Corresponding author: Donald Zack, Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Smith Building—Room 3029, 400 N. Broadway, Baltimore, MD 21287, USA.

Tel.: (410) 502–5230;

fax: (410) 502–5382;



Alternative splicing is highly regulated in tissue-specific and development-specific patterns, and it has been estimated that 15% of disease-causing point mutations affect pre-mRNA splicing. In this review, we consider the cis-acting splice site and trans-acting splicing factor mutations that affect pre-mRNA splicing and contribute to retinal degeneration. Numerous splice site mutations have been identified in retinitis pigmentosa (RP) and various cone-rod dystrophies. Mutations in alternatively spliced retina-specific exons of the widely expressed RPGR and COL2A1 genes lead primarily to X-linked RP and ocular variants of Stickler syndrome, respectively. Furthermore, mutations in general pre-mRNA splicing factors, such as PRPF31, PRPF8, and PRPF3, predominantly cause autosomal dominant RP. These findings suggest an important role for pre-mRNA splicing in retinal homeostasis and the pathogenesis of retinal degenerative diseases. The development of novel therapeutic strategies to modulate aberrant splicing, including small molecule-based therapies, has the potential to lead to new treatments for retinal degenerative diseases.

Retinitis pigmentosa (RP) is a heterogeneous group of inherited retinal degenerative disorders that affects approximately 1 in 4000 in the United States [1]. Patients initially experience night blindness and peripheral vision loss, with central retinal involvement generally becoming prominent only later in life. Clinical assessment reveals atrophy of the retinal pigment epithelium (RPE) with bone spicule pigmentation in the peripheral retina, waxy pallor of the optic disc and retinal vessel attenuation. Mutations in more than 45 genes that can cause non-syndromic RP have been identified (, including rhodopsin, affected in 25% of autosomal dominant RP (adRP), USH2A, affected in 20% of autosomal recessive RP (arRP), and RPGR, affected in 70% of X-linked RP (XLRP) [2]. Although non-syndromic RP, by definition, has an exclusively ocular phenotype, not all of the disease-causing genes are preferentially or exclusively expressed in the retina. As one example, relevant to the focus of this review, mutations in factors that are ubiquitously expressed and important for the general process of pre-mRNA splicing have been identified as causes of adRP.

Eukaryotic pre-mRNA splicing is a process by which intervening intronic sequences are removed and the remaining exonic segments are ligated to form mature mRNA molecules (Fig. 1a) [3]. Splicing occurs in the spliceosome, a complex of five small nuclear ribonucleoproteins (snRNPs) and additional factors, which catalyzes the two transesterification reactions needed to join each donor splice site, located at the 5′ end of the intron, to its corresponding acceptor splice site, located at the 3′ end of the intron. A branch point adenosine residue, located within the intron, serves as the nucleophile for the first transesterification reaction. The U1 snRNP binds the 5′ splice site, the U2 snRNP binds the branch point adenosine, and U2AF binds the intronic polypyrimidine tract of the 3′ splice site. The U4/U6/U5 tri-snRNP is then recruited, and a series of conformational changes occurs, allowing joining of adjacent exons and the removal of the intron lariat.

Figure 1.

(a) Eukaryotic pre-mRNA splicing (b) Mechanisms of alternative splicing.

Approximately 80% of human exons are less than 200 bases in length [4], and they are separated by introns that may be up to many thousands of bases long, but despite this complexity, pre-mRNA splicing nevertheless occurs with high fidelity. Splice site selection and recognition are mediated by the strength of the splice site sequence, the presence of cis-acting regulatory elements, and the availability of trans-acting splicing factors [5]. Exon definition allows the splice sites flanking each exon to be recognized as paired, via exon-bridging interactions between snRNPs and other splicing factors. Non-splice site RNA sequences can also enhance or repress spliceosome activity. Serine–argine (SR) proteins are exonic splicing enhancers that bind purine-rich exonic splicing enhancer element sequences to promote both constitutive and regulated splicing activity by enhancing usage of weak upstream 3′ splice sites, stabilizing intron-spanning interactions, and promoting exon-bridging interactions by binding to both U2AF and U1 [6]. A number of other factors have been identified as enhancer or repressor splicing regulators, and the combinatorial binding of these different splicing factors, whose expression levels are also regulated, leads to high fidelity spatiotemporal exon/intron definition [7, 8]. Alternative splicing can result from alternative 5′ splice site usage, alternative 3′ splice site usage, exon skipping, or intron retention, and these mechanisms allow for a single gene to encode multiple protein products that can have vastly different functional properties (Fig. 1b). It is estimated that at least 74% of human genes are alternatively spliced [9], and of these, at least 10–30% have tissue-specific splice isoforms [10]. Alternative splicing is highly regulated in tissue-specific and development-specific patterns, and neurons have a particularly high abundance of differentially spliced genes [11]. It is estimated that 15% of disease-causing point mutations affect pre-mRNA splicing [12]. In this review, we consider the role of cis-acting splice site mutations and mutations in trans-acting splicing factors in the pathogenesis of retinal degenerative disease.

Cis-acting splice site mutations

A myriad of splice site mutations have been identified in patients with RP, Usher syndrome, cone-rod dystrophy, and other retinal degenerative diseases (Table 1), and assays have been performed to characterize the functional effects of some of these splice site mutations in vitro. Most of the mutations disrupt a consensus splice site sequence and cause exon skipping, but some result in intron inclusion, novel exon inclusion, or the usage of cryptic upstream or downstream splice sites. The resultant insertions or deletions in the protein sequence, often accompanied by frameshift and premature termination, disrupt conserved or functional protein domains and result in retinal degeneration. A detailed discussion of these cis-acting splice site mutations is included in the Appendix S1. Additionally, although they will not be considered further in this review, there are also a number of rodent models of retinal degeneration that result from cis-acting splicing defects or large deletions in the genomic DNA that result in exon skipping, including the rd16 mouse, in which exons 35–39 of Cep290 are skipped [13]; the RCS rat, in which exon 2 of Mertk is skipped [14]; the rd6 mouse, in which exon 4 of Mfrp is skipped [15]; and the rd7 mouse, in which exons 4–5 of Nr2e3 are skipped [16].

Table 1. Splice site mutations associated with retinal degenerationa
Retinitis pigmentosa  
  1. IVSX+n, nth base of intron X; IVS−n, nth base from the end of intron X; IVS, intervening sequence; c.n, nth base of CDS.

  2. a

    Refer to Appendix S1 for supplementary references for the respective diseases.

RhodopsinIVS4+2 G>TSkipping of exon 4 due to disruption of donor splice site
 IVS4−1 G>ADeletion of exon 5 and 143 bases of 3′ untranslated region
 IVS4−1 G>T 
 30 bp deletion including acceptor splice site of intron 4 and first 7 bases of exon 5, 150 bp insertion 
β-PDEIVS2−1 G>TMultiple alternatively spliced transcripts: intron 2 inclusion, alternative 3' splice site in intron 3
 IVS3+1 G>T 
 IVS14+1 A>G 
BBS8IVS1−2 A>GSkipping of photoreceptor-specific alternatively spliced exon 2a
 IVS12+1 G>C 
MERTKIVS16+1 G>TSkipping of exon 16, frameshift, premature termination in exon 17
 IVS40+5 G>A 
OFD1IVS9+706 A>GInsertion of cryptic exon between exons 9 and 10, frameshift
Usher syndrome
USH1CIVS5−2 delA 
 IVS1+1 G>T 
 IVS5+1 G>A 
 IVS14+6 T>GSkipping of exon 14; 31 base deletion from exon 14
CDH23IVS29−1 G>TSkipping of exon 30; 51 base deletion from exon 30
 c.4488 G>CAlternative 5′ splice site within intron 35, 80 amino acid insertion, premature termination
 IVS45−9 G>AInsertion of 7 bases of intron 45
 IVS51+5 G>ASkipping of exon 51
 c.7872 G>AInsertion of 86 bases of intron 54
USH2AIVS2−14 G>AInsertion of 12 bases of intron 2
 c.949 C>A193 base deletion of exon 6
 IVS10−2 A>GSkipping of exon 11
 IVS12+5 G>ASkipping of exon 12; alternative 5′ splice site within exon 12, 30 base pair deletion
 IVS12−1 G>C7 base deletion of exon 13
 c.2993G>AArg998Lys; skipping of exon 14
 IVS17+3 A>TSkipping of exon 17
 c.4576-4579dupGGGT50 base deletion of exon 21
 IVS25−6 T>ASkipping of exon 26
 IVS26+1 G>CSkipping of exon 26
 IVS40−8 C>G7 base insertion of intron 40
 IVS40−3 C>G2 base insertion of intron 40
 IVS43−17 A>G39 base deletion of exon 44
 IVS53+3 A>G82 base deletion from exon 53
 IVS66+39 C>TAlternative 5′ splice site within intron 66, 37 base insertion
MYO7Ac.592 G>AAla198Thr; skipping of exon 6
 IVS13−8 C>G7 base insertion of intron 13; skipping of exon 14
 c.1935 G>AMet645Ile; skipping of exon 16
 IVS19−1 G>TSkipping of exon 20
 IVS22−9 A>G8 base insertion of intron 22
 c.3503 G>CArg1168Pro; skipping of exon 27
 c.5856 G>ASkipping of exon 42
 c.5944 G>AGly1982Arg; skipping of exon 43
Cone rod dystrophy and additional retinal degenerative diseases
RLBP1c.342 G>A 
 IVS3+2 T>C 
 IVS8−6 T>A 
 IVS9−2 A>G 
 IVS15+1 G>A 
 IVS19−2 A>G 
 IVS23+5 delG 
 IVS23−1 G>A 
 IVS25−2 A>G 
 IVS29+1 G>A 
 IVS29−15del23Skipping of exons 28 and 29; skipping of exon 29; skipping of exon 29 and first 114 bases of exon 30
 IVS31−1 G>T 
 IVS37+1 G>A 
 IVS41−2 A>C 
 IVS46−1 G>T 
 IVS47+1 G>A 
 IVS47+1 G>C 
C8orf38IVS1−2 A>G 
CACNA1FIVS24+1 G>APremature stop in intron 24
 IVS28−1 GCGTC>TGGMultiple aberrantly spliced products
 IVS40−2 A>GSkipping of exon 41, premature stop in exon 42
CEP290IVS26+1655 A>GInsertion of cryptic exon between exons 26 and 27
 c.451 C>TSkipping of exon 7; skipping of exon 7 and 8

Alternative splice isoforms

Stickler syndrome type I, an autosomal dominant disease caused by mutations in COL2A1, is characterized by acquired radial perivascular retinal degeneration, congenital vitreous syneresis, high myopia, early-onset cataract, glaucoma, junvenile osteoarthritis, sensorineural hearing loss, and craniofacial abnormalities. In the vitreous, COL2A1 includes exon 2, whereas exon 2 is absent in most other tissues, including cartilage [17]. In a large family from the Southwestern United States with Stickler syndrome type I, the causative mutation was Cys86X, a premature stop codon in the alternatively spliced exon 2 [18]. Interestingly, as this mutated transcript is expressed specifically in the eye, only 4 of 100 people in this family showed any of the extraocular manifestations characteristic of Stickler syndrome. A frameshift mutation in exon 2 leading to premature termination, Cys57X, was also identified in a French-Canadian family with a similar autosomal dominant vitreoretinal degeneration [19].

The retinitis pigmentosa GTPase regulator (RPGR) localizes to the connecting cilium of photoreceptors and plays a role in microtubule organization and cellular transport [20]. RPGR undergoes extensive alternative splicing and has two main transcripts, a widely expressed RPGRexon1–19 form and a retina-specific RPGRORF15 form. Mutations in RPGR have been identified as the cause of 72% of XLRP, and 80% of these mutations occur in the purine-rich ORF15 [21]. Many XLRP mutations, including splice site mutations [22-25], have been identified throughout the RPGRORF15 transcript, suggesting that each of the contained exons is necessary for retinal function, but interestingly, no mutations have been identified in exons 16–19 [26]. The ratio of RPGRexon1–19 to RPGRORF15 is important to the integrity of the adult retina in mouse, and overexpression of RPGRexon1–19 leads to severe retinal degeneration [27]. It has also been shown that certain truncated forms of RPGR can have dominant gain-of-function effects [28]. Another alternatively spliced exon, exon 9a, was identified 418 base pairs downstream of the 5′ splice site of intron 9 and is 136 bases long. This exon is present in approximately 4% of retinal transcripts and is enriched in cone inner segments. An intronic G to A substitution between exon 9 and exon 9a was identified in a family with XLRP and increases the percentage of transcripts containing exon 9a [29]. Mutations in tissue-specific exons and mutations that affect the relative prevalence of tissue-specific transcripts permit mutations in ubiquitously expressed genes to result in primarily ocular disease [30] (Table 2).

Table 2. Alternative splice isoforms associated with retinal degeneration
  1. IVSX+n, nth base of intron X; IVS−n, nth base from the end of intron X; c.n, nth base of CDS.

COL2A1Cys86XPremature termination in alternatively spliced exon[18]
Cys57XPremature termination in alternatively spliced exon[19]
RPGRORF15, variousVarious [21-25]
IVS9+363 G>AIncreased inclusion of exon 9a[29]

Splicing factor mutations

PRPF31 encodes a homolog to the yeast pre-mRNA splicing factor Prp31p, and mutations in this gene have been identified as a cause of adRP [31]. In S. cerevisiae, Prp31p is not necessary for the formation of the U4/U6/U5 tri-snRNP but is instead responsible for recruiting the tri-SNP to the spliceosome. PRPF31 in humans is required for tri-SNP formation and spliceosome activity [32]. Seven PRPF31 mutations have been identified in British families with adRP, including two intronic mutations that disrupt the 5′ and 3′ splice sites of intron 6, Ala216Pro and Ala194Glu mutations in exon 7, two frameshift mutations leading to premature termination, and an in-frame insertion of 11 amino acids [33]. A 12 base pair deletion in exon 5 causing an in-frame deletion of His111Lys112Phe113Ile114, which includes the highly conserved His111 residue, has also been identified in a Chinese family with adRP [34]. A G to A substitution in the last base of intron 5 disrupts the 3′ splice site, causes a one base pair deletion in the first codon of exon 6, frameshift, and premature termination in another large Chinese family with adRP [35]. Three nonsense mutations in exon 8 have also been identified in Spanish families with adRP [36]. In a cohort of French adRP patients, it was found that 6.7% have mutations in PRPF31 [37].

Studies to evaluate the effects of PRPF31 mutations on pre-mRNA splicing have shown a range of results. The AD5 and SP117 PRPF31 mutants, which have an 11 base pair deletion after amino acid 371 and a single base pair insertion after amino acid 256, respectively, were co-expressed with minigene constructs for RDS and FSCN2. Both mutants showed impaired splicing of RDS intron 1, but only the AD5 mutant showed impaired splicing of FSCN2 intron 3 [38]. The PRPF31 mutants containing the N-terminal 371 or 256 amino acids showed reduced splicing of intron 3 of rhodopsin, and in primary retinal cell cultures, led to reduced rhodopsin protein expression and apoptosis [39]. In contrast, PRPF31 Ala194Glu and Ala216Pro mutants showed only mild effects on in vitro splicing function [40]. Nevertheless, it has been hypothesized that more significant deficiencies may manifest in the setting of high splicing activity demand.

Mutations in PRPF8 have also been implicated in severe, early-onset adRP [41]. PRPF8 is a component of the U5 snRNP and can interact with the 5′ splice site, the branch point adenosine, and the 3′ splice site in pre-mRNA, suggesting it maybe a cofactor in the catalytic domain of the spliceosome [42]. Seven missense mutations (His2309Pro, His2309Arg, Arg2310Lys, Pro2301Thr, Phe2304Leu, Arg2310Gly, and Phe2314Leu) have been identified in South African families [41]. Three frameshift mutations, a mutation disrupting the stop codon, and the Arg2310Gly missense mutation have also been reported in Spanish families [36]. Interestingly, all of these mutations lie in PRPF8 exon 42.

Several adRP-causing mutations have also been identified in PRPF3, which encodes a U4/U6 associated splicing factor required for spliceosome assembly and U4/U6/U5 tri-snRNP stability [43, 44]. Three missense mutations have been identified: Ala489Asp [45], Pro493Ser, and Thr494Met [43]. Whereas wild-type PRPF3 is not especially abundant in photoreceptors, T494M mutant PRPF3 has been shown to form large aggregates of mislocalized proteins in photoreceptors in vitro that cause apoptosis, a phenomenon not observed in epithelial or fibroblast cell lines, perhaps due to an inability to recycle the PRPF3 splicing factor [44]. Notably, all of these mutations cluster in a conserved C-terminal region flanked by binding sites for other splicing factors, including PAP-1 [46].

Two adRP-causing missense mutations, His137Leu and Asp170Gly, have also been reported in PAP-1, another component of the U4/U6/U5 tri-snRNP [47]. PRPF6 is an additional splicing factor that interacts with components of the U4/U6/U5 snRNP, and the Arg729Trp mutation has been identified in a patient with adRP [48]. Immortalized lymphoblasts from this patient showed intranuclear aggregates of PRPF6, suggesting that the mutation leads to a defect in tri-snRNP assembly or recycling, and in vitro splicing assays showed impaired splicing activity. The Ser1087Leu [49] and Arg1090Leu [50] mutations in SNRNP2000 have also been identified in Chinese families with adRP, and they impair the ability of SNRNP200 to unwind U4/U6 snRNAs (Table 3).

Table 3. Splicing factor mutations associated with retinal degeneration
  1. IVSX+n, nth base of intron X; IVS−n, nth base from the end of intron X; c.n, nth base of CDS.

PRPF31c.269-273 delFrameshift, premature termination[37]
c.331-342 delDeletion of His111Lys112Phe113Ile114[34]
IVS5–1 G>A1 base deletion of exon 6, frameshift, premature termination[35]
IVS6+2 T>C [37]
IVS6+3 A>GInactivate 5' splice site[33]
IVS6-3 to IVS5-45 delInactivate 3' splice site[33]
c.580-581 dup 33 basesFrameshift, in-frame 11 amino acid insertion[33]
c.581 C>AAla194Glu[33]
c.666 dupFrameshift, premature termination[37]
c.646 G>CAla216Pro[33]
c.709-734 dupFrameshift, premature termination[37]
c.732-737 delins 20 basesFrameshift, premature termination[36]
c.769-770 ins A (SP117)Frameshift, premature termination; impaired splicing of RDS intron 1; impaired splicing of rhodopsin intron 3 [33, 36, 38, 39]
c.828-829 delCAFrameshift, premature termination[36]
c.873-897 dupFrameshift, premature termination[37]
c.997 delGFrameshift, premature termination[37]
c.1115-1125 del (AD5)Frameshift, premature termination; impaired splicing of RDS intron 1 and FSCN2 intron 3; impaired splicing of rhodopsin intron 3 [33, 38, 39]
PRPF8c.6901 C>APro2301Thr[41]
c.6912 C>GPhe2304Leu[41]
c.6926 A>CHis2309Pro[41]
c.6926 A>GHis2309Arg[41]
c.6928 A>GArg2310Gly [36, 41]
c.6929 G>AArg2310Lys[41]
c.6942 C>APhe2314Leu[41]
c.6943-6944 delCFrameshift, premature termination[36]
c.6974-6994 del21Frameshift, premature termination[36]
c.6893-6896 delins7Frameshift, premature termination[36]
c.7006 T>CDisruption of stop codon, protein extension[36]
PRPF3c.1466 C>AAla489Asp[45]
c.1477 C>TPro493Ser[43]
c.1481 C>TThr494Met [43, 44]
PAP1c.410 A>THis137Leu[47]
c.509 A>GAsp170Gly[47]
PRPF6c.2185 C>TArg729Trp; defect in tri-snRNP assembly or recycling[48]
SNRNP2000c.3260 C>TSer1087Leu[49]
c.3269 G>TArg1090Leu[50]

There have been a number of proposed models for how mutations in ubiquitously expressed splicing factors, all of which are associated with the U4/U6/U5 snRNP, can lead to a retina-specific autosomal dominant disease, including haploinsufficiency, impaired spliceosome assembly, impaired interaction with a photoreceptor-specific splicing cofactor, or gain-of-function toxicity [51]. The Prpf3-Thr494Met, Prpf8-His2309Pro, and Prpf31-knockout mouse models of splicing factor adRP all demonstrate some aspects of retinal degeneration, with a relatively late onset [52]. In the mouse models, the primary cell affected appears to be the RPE, but whether this is the case in humans is unclear. One study indicated that adRP-causing splicing factor mutations disrupt the relative ratios of snRNAs, the composition of the U4/U6/U5 snRNPs, and spliceosome assembly and therefore are likely to have systemic effects on pre-mRNA splicing that, for reasons that remain to be elucidated, are tolerated in other tissues but not in the retina [53]. The expression levels of PRPF3, PRPF31, PRPC8, and the 5 snRNPs are higher in the retina than in other tissues in normal adult mice, suggesting that the retina, one of the most metabolically active tissues in the body, may have higher basal splicing requirements than other tissues [54]. Splicing factor mutations may manifest uniquely in the retina as adRP due to pre-mRNA splicing deficiencies that only occur in the setting of high demand.

Small molecules to modulate pre-mRNA splicing

Aberrant pre-mRNA splicing contributes profoundly to human disease, and the development of novel therapeutic strategies to modulate pre-mRNA splicing is of great clinical interest. Lentiviral delivery of U1snRNA engineered to bind mutated donor splice sites has shown moderate efficacy in rescuing splicing of BBS1 [55] and RPGR [24] in fibroblasts derived from patients with Bardet-Biedl syndrome and XLRP, respectively. siRNA strategies have been investigated to target variant splice isoforms resulting from adRP-associated splice site mutations in rhodopsin [56]. Antisense oligonucleotide and related approaches are also being developed to modulate splicing in Duchenne muscular dystrophy, spinal muscular atrophy (SMA), Hutchinson-Gilford progeria syndrome, and myotonic dystrophy [57, 58].

Some notable successes have been achieved using small molecules therapies to modulate splicing. SMA, an autosomal recessive disease characterized by lower motor neuron degeneration leading to progressive proximal muscle atrophy and weakness, is caused by loss of function mutations in SMN1. SMN2 encodes a nearly identical protein, but its mRNA transcript generally skips exon 7 and leads to the production of a truncated protein product that cannot compensate for the decreased levels of functional SMN1 [59]. In a small molecule screen of Epstein-Barr virus-transformed lymphoid cells derived from SMA patients, sodium butyrate was identified as a modulator of SMN2 splicing that increased exon 7 inclusion and the production of full-length SMN2 transcripts and protein [60]. In the same study, sodium butyrate treatment in a murine model of SMA improved tail muscle tone and prolonged survival. The anthracycline aclarubicin [61] and the tetracycline-like compound PTK-SMA1 [62] have also been shown to increase inclusion of exon 7. The bacteria-derived pladienolides [63], FR901464, and herboxidiene are inhibitors of the spliceosome component SF3b and prevent binding of U2 snRNA to the branch point adenosine, leading to aberrant splicing and apoptosis in cancer cells [64]. Derivatives such as sudemycins also demonstrate anti-tumor activity in human tumor cell lines and xenograft models [65].

Tau is a microtubule-associated protein that is alternatively spliced in humans, and mutations that promote the inclusion of exon 10 are associated with frontotemporal dementia and parkinsonism. Cdc2-like kinases 1–4 (CLK 1–4) phosphorylate SR proteins and promote exon 10 skipping in tau, suggesting that using small molecules to modulate the phosphorylation of SR proteins or the kinases and phosphatases that regulate them may also be a viable therapeutic strategy to target aberrant pre-mRNA splicing [66, 67]. A benzothiazole compound named TG003 is a CLK family inhibitor and blocks the activity of the SR protein SF2/ASF [68]. Inhibition of CLK1 by TG003 reduces influenza virus replication by inhibiting splicing of the viral M2 pre-mRNA [69]. TG003 can also promote skipping of exon 31 of the dystrophin gene in myoblasts derived from patients with premature stop codons in this exon [70]. Vascular endothelial growth factor (VEGF) has a pro-angiogenic form, VEGF165, and an anti-angiogenic form, VEGF165b, that are produced as alternative splice isoforms. SRPIN340, an inhibitor of the SR protein kinase SRPK1/2, promotes the anti-angiogenic form and can inhibit angiogenesis in a mouse model of retinal neovascularization [71]. Finally, a screen of small molecule splicing modulators in a human hepatocellular carcinoma cell line revealed that the potassium sparing diuretic amiloride was able to revert oncogenic splicing of BCL-X, HIPK3, and RON/MISTR1 [72].

Concluding remarks

It is clear that abnormalities of alternative splicing can play an important role in the development of RP and other retinal degenerative diseases. The advent of next-generation sequencing technologies and massively parallel high-throughput RNA sequencing (RNA-seq) opens unprecedented opportunities to study tissue-specific alternative splicing, characterize disease-relevant cis-acting splice variants, and assess the impact of trans-acting splicing factor mutations across the transcriptome. A more thorough understanding of the contribution of aberrant splicing to retinal degeneration is crucial to the development of novel therapeutic strategies. Small molecule and other modulators of alternative splicing have shown promise in the context of a variety of human diseases, and provide hope that it will be possible to develop analogous approaches for the treatment of retinal degenerations and other forms of ophthalmic disease that are due to abnormalities of RNA splicing.


This work was supported by research grants from the National Institutes of Health (Medical Scientist Training Program Grant T32GM007309 (M. M. L.); R01EY009769 (D. J. Z.); core grant P30EY001765), Foundation Fighting Blindness, and unrestricted funds from Research to Prevent Blindness, Inc., and generous gifts from Mr and Mrs Robert and Clarice Smith and the Guerrieri Family Foundation.